

## CONFERENCE PROGRAM

MONDAY, SEPTEMBER 1, 2014

---

08:15 – 08:30      OPENING SESSION      **El Prado Room**

---

OPENING REMARKS AND GREETINGS  
**M. Bialer**, Organizing Committee, Israel

GREETINGS  
**E. Perucca**, Organizing Committee and ILAE President, Italy

---

08:30 – 11:00      SYMPOSIUM ON CONQUERING      **El Prado Room**  
PHARMACORESISTANT EPILEPSY:  
DEBATES

---

Chairs:      **R. Katz**, USA  
                 **H.S. White**, USA

08:30      UNDERSTANDING THE MECHANISMS OF  
PHARMACORESISTANCE *WILL* LEAD TO NEW TARGETS  
AND TREATMENTS  
YES: **W. Löscher**, Germany      NO: **G.J. Sills**, UK

08:50      Discussion

09:00      PHARMACORESISTANCE IS A DYNAMIC PROCESS THAT  
DEVELOPS WITH TIME  
YES: **J.A. French**, USA      NO: **M.J. Brodie**, UK

09:20      Discussion

09:30      PHARMACORESISTANCE *CAN* BE PREDICTED  
YES: **P. Ryvlin**, France      NO: **S.D. Shorvon**, UK

09:50      Discussion

**MONDAY, SEPTEMBER 1, 2014 (Continued)**

---

08:30 – 11:00 SYMPOSIUM ON CONQUERING PHARMACORESISTANT EPILEPSY: DEBATES Continued **El Prado Room**

---

10:00 PHARMACORESISTANCE CAN BE PREVENTED  
YES: **H. Klitgaard**, Belgium NO: **C. Elger**, Germany

10:20 Discussion

10:30 SHOULD THE CURRENT APPROACH TO THERAPY DISCOVERY BE MODIFIED?  
YES: **D. Schmidt**, Germany NO: **M.A. Rogawski**, USA

10:50 Discussion

11:00 *Coffee*

---

11:30 – 12:30 PLENARY LECTURES **El Prado Room**

---

Chairs: **R. Katz**, USA  
**H.S. White**, USA

11:30 PHARMACORESISTANCE: CURRENT APPROACH EMPLOYED BY THE NIH-NINDS ANTICONVULSANT SCREENING PROJECT  
**J.H. Kehne**, USA and **H.S. White**, USA

11:50 Discussion

12:00 PHARMACORESISTANCE FROM A REGULATORY PERSPECTIVE: WHAT INFORMATION IS IMPORTANT?  
**R. Katz**, USA

12:20 Discussion



**MONDAY, SEPTEMBER 1, 2014 (Continued)**

---

15:50 – 18:00    INNOVATIVE EMERGENCY                    **El Prado Room**  
                         TREATMENTS Continued

---

- 15:50            BUCCAL MIDAZOLAM  
*ViroPharma sprl., UK*  
Presented by **S.D. Shorvon**, University College London, UK
- 16:05            Discussion
- 16:15            IV CARBAMAZEPINE  
**D. Lee**, *Lundbeck Inc., USA*
- 16:30            Discussion
- 16:40            IV LACOSAMIDE  
**K.J. Werhahn**, *UCB Pharma, Belgium*
- 16:55            Discussion
- 17:05            IV LEVETIRACETAM  
*UCB, Belgium*  
Presented by **E. Trinka**, Paracelsus Medical University, Austria
- 17:20            Discussion
- 17:30            PROPOFOL HEMISUCCINATE  
*Epalex Corporation*  
Presented by **M.A. Rogawski**, University of California, USA
- 17:45            Discussion



**TUESDAY, SEPTEMBER 2, 2014 (Continued)**

10:55      *Coffee*

---

11:25 – 13:05      DRUGS IN DEVELOPMENT      **El Prado Room**  
SESSION 2

---

Chairs:      **T. Tomson**, Sweden  
                 **H.S. White**, USA

11:25      CANNABIDIVARIN (GWP 420006)  
                 *GW Pharmaceuticals, UK*  
                 Presented by **B.J. Whalley**, Reading University, UK

11:40      Discussion

11:50      2-DEOXY-(D)-GLUCOSE  
                 Presented by **T.P. Sutula**, University of Wisconsin, USA

12:05      Discussion

12:15      EVEROLIMUS  
                 Presented by **P. Curatolo**, "Tor Vergata" University  
                 Hospital, Rome, Italy

12:30      Discussion

12:40      GANAXOLONE  
                 **G.M. Farfel**, *Marinus Pharmaceuticals, USA*

12:55      Discussion

13:05      *Lunch*







**WEDNESDAY, SEPTEMBER 3, 2014**

---

08:00 – 11:15      PROGRESS REPORT ON                      **El Prado Room**  
SECOND-GENERATION TREATMENTS

---

Chairs:      **E. Perucca**, Italy  
                 **T. Tomson**, Sweden

08:00      CLOBAZAM  
                 **J. Isojärvi**, *Lundbeck Inc.*, USA

08:15      Discussion

08:25      ESLICARBAZEPINE ACETATE  
                 BIAL Portugal  
                 Presented by **E. Trinka**, Paracelsus Medical University, Austria

08:40      Discussion

08:50      LACOSAMIDE  
                 **K.J. Werhahn**, *UCB Pharma*, Belgium

09:05      Discussion

09:15      PERAMPANEL  
                 **A. Laurenza**, *Eisai Inc.*, USA

09:30      Discussion

09:40      PREGABALIN  
                 **V. Pitman**, *Pfizer Inc.*, USA

09:55      Discussion

10:05      RETIGABINE  
                 Presented by **E. Trinka**, Paracelsus Medical University,  
                 Austria

10:20      Discussion

**WEDNESDAY, SEPTEMBER 3, 2014 (Continued)**

---

08:00 – 11:15      PROGRESS REPORT ON                      **El Prado Room**  
SECOND-GENERATION TREATMENTS Continued

---

10:30              STIRIPENTOL  
*Biocodex, France*  
Presented by **E. Wirrell**, The Mayo Clinics, USA

10:45              Discussion

10:55              VIGABATRIN  
**J. Isojärvi**, Lundbeck Inc., USA

11:10              Discussion

11:15              *Tapas Brunch*

---

12:00 – 14:05      NEW METHODS AND                      **El Prado Room**  
FORMULATIONS

---

Chairs:            **S.I. Johannessen**, Norway  
                      **E. Trink**, Austria

12:00              ASPIRE SR : VNS THERAPY WITH CARDIAC-BASED  
SEIZURE DETECTION  
**S. Sabesan**, *Cyberonics, USA*

12:15              Discussion

12:25              SEIZURE SEVERITY AS A CLINICAL TRIAL END POINT  
**O. D'Cruz**, *Cyberonics, USA*

12:40              Discussion

12:50              USL255 - A ONCE DAILY TOPIRAMATE EXTENDED-  
RELEASE FORMULATION  
*Upsher-Smith Laboratories, Inc., USA*  
Presented by **I. Blatt**, Chaim Sheba Medical Center,  
Israel

13:05              Discussion

**WEDNESDAY, SEPTEMBER 3, 2014 (Continued)**

---

12:00 – 14:05      NEW METHODS AND FORMULATIONS Continued      **EI Prado Room**

---

13:15      OXCARBAZEPINE MODIFIED-RELEASE *VERSUS*  
ESLICARBAZEPINE ACETATE  
*Desitin Arzneimittel GmbH, Germany*  
Presented by **C. Elger**, University of Bonn, Germany

13:30      Discussion

13:40      PREGABALIN CONTROLLED-RELEASE  
FORMULATION  
**V. Pitman**, *Pfizer Inc., USA*

13:55      Discussion

---

14:05 – 14:30      CLOSING KEYNOTE LECTURE      **EI Prado Room**

---

14:05      IMPROVING CLINICAL AED DEVELOPMENT  
**J.A. French**, USA

14:30      Conclusion of Conference

---

## POSTER PRESENTATIONS

---

Board No.

1. THERAPEUTIC TREATMENT OF ACUTE BEHAVIORAL SEIZURES IN THE THEILER'S MURINE ENCEPHALOMYELITIS VIRUS MODEL OF ACQUIRED EPILEPSY IMPROVES LONG-TERM BEHAVIORAL OUTCOME  
**M.L. Barker-Haliski**, E.J. Dahle, T.H. Pruess, T.D. Heck, F. Vanegas, K.S. Wilcox, H.S. White, USA
2. THE ROLE OF DRUG COMBINATIONS IN THERAPY OF REFRACTORY EPILEPSY - CLINICAL OBSERVATIONS  
**P. Czapinski**, E.K. Czapinska, Poland
3. STUDY ON THE CHARACTERISTICS OF THE TREATMENT OF THE DIFFERENT TYPES OF STATUS EPILEPTICUS IN CLINICAL PRACTICE  
**M.A. De La Morena Vicente**, J.J. Granizo Martínez, J. Ojeda Ruiz de Luna, A. Peláez Hidalgo, M. Luque Alarcón, F.J. Navacerrada Barrero, S. Al Hussayni Husseini, E. García Cobos, L. Ballesteros Plaza, G. De Las Casas Cámara, I. Viúdez Jiménez, Spain
4. IMPROVING THE DEVELOPMENT OF ANTIEPILEPTIC DRUGS: PRECLINICAL SOLUTIONS COMBINING CHRONIC MODELS OF EPILEPSY AND EEG  
**V. Duveau**, C. Bouyssieres, C. Dumont, B. Pouyatos, C. Roucard, France
5. EFFECTS OF TOPIRAMATE ON GROWTH AND DEVELOPMENT IN CHILDREN WITH NEW OR RECENT- ONSET EPILEPSY: A PHASE-4 RANDOMIZED, ACTIVE-CONTROLLED STUDY  
**L. Ford**, Y. Shi, P. Manitpisitkul, USA
6. TOPIRAMATE AS MIGRAINE PROPHYLAXIS IN PEDIATRIC PATIENTS: RESULTS OF AN INTEGRATED ANALYSIS  
**L. Ford**, Y. Shi, K. Shalayda, P. Manitpisitkul, USA

---

## POSTER PRESENTATIONS

---

Board No.

7. THE EFFECT OF LEVETIRACETAM ON THE INTERICTAL EEG IN CHILDREN WITH REFRACTORY EPILEPSY  
E. Heyman, S. Gilat, E. Lahat, N. Levin, R. Sheinberg, M. Berkovitch, **R. Gandelman-Marton**, Israel
8. COVARIATE ANALYSIS SHOWS A MINOR ROLE FOR CLOBAZAM AND NORCLOBAZAM IN THE ANTIEPILEPTIC EFFICACY OF CO-ADMINISTERED STIRIPENTOL  
H. Mekonnen, M. Koga, K. Clarence-Smith, **K. Kazempour**, USA
9. MIDAZOLAM PLASMA LEVELS AFTER THE ADMINISTRATION OF DIFFERENT GALENIC NASAL FORMULATION  
**M.C. Kravetz**, O.A. Martinez, M. Sol Pacha, J.E. Patzi, E. Otamendi, A. Lazarowski, I. Lagger, F. Buontempo, E. Bernabeu, M.A. Moreton, D.A. Chiappetta, G. Bramuglia, Argentina
10. EXPERIENCE FROM THERAPEUTIC DRUG MONITORING OF LACOSAMIDE IN CLINICAL PRACTICE IN NORWAY  
**C.J. Landmark**, A. Baftiu, S.I. Johannessen, Norway
11. EXPERIENCE FROM THERAPEUTIC DRUG MONITORING OF CLOBAZAM AND ITS METABOLITE DESMETHYLCLOBAZAM IN CLINICAL PRACTICE  
M.L. Burns, S.I. Johannessen, **C.J. Landmark**, Norway
12. HERITAGE FEATURES OF RARE EPILEPTIC DISEASES IN GEORGIAN POPULATION  
**M. Lazariashvili**, S. Kasradze, Georgia
13. PHARMACOKINETIC AND PHARMACODYNAMIC ANALYSIS OF CNS-ACTIVE CONSTITUTIONAL ISOMERS OF VALNOCTAMIDE (VCD) AND SEC-BUTYLPROPYLACETAMIDE (SPD) - AMIDE DERIVATIVES OF VALPROIC ACID  
**H. Mawasi**, T. Shekh-Ahmad, J.H. Mcdonough, R.H. Finnell, B.J. Wlodarczyk, M. Bialer, Israel

---

## POSTER PRESENTATIONS

---

Board No.

14. MECHANISMS OF ACTION OF ANTI-SEIZURE DRUGS AND THE ANTICONVULSANT SCREENING PROGRAM OF THE NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE  
**R.J. Porter**, H. Kupferberg, B.J. Hessie, USA
15. VPA RETAINS SUPPRESSIVE PPR EFFECT AT STEADY-STATE WITH LESS VARIABILITY THAN CBZ: RETROSPECTIVE ANALYSIS OF 239 PHOTSENSITIVE CLINIC PATIENTS  
**R.C. Reed**, P. Timmings, P. Parisi, D.K. Trenite, USA
16. STEREOSELECTIVE ANTICONVULSANT AND PHARMACOKINETIC ANALYSIS OF VALNOCTAMIDE, A CNS-ACTIVE DERIVATIVE OF VALPROIC ACID WITH LOW TERATOGENIC POTENTIAL  
**T. Shekh-Ahmad**, N. Hen, B. Yagen, J.H. McDonough, R.H. Finnell, B.J. Wlodarczyk, M.Bialer, Israel
17. ARE HLA-A MARKERS USEFUL IN PREDICTING MILD RASH FROM AEDs?  
**M. Shirzadi**, K. Thorstensen, G. Helde, T. Moen, E. Brodtkorb, Norway
18. ALLOPREGNANOLONE IN PATIENTS WITH PCHD19 RELATED EPILEPSY: NEW THERAPEUTIC TARGETS  
**M. Trivisano**, N. Pietrafusa, A. Benvenga, A. Terracciano, N. Specchio, Italy